STAT+: Biopharma industry at odds over impact of Treasury’s new China rule

An exemption for a common kind of biopharma deal is at the heart of disagreements over the proposal.

<p>An exemption for a common kind of biopharma deal is at the heart of disagreements over the proposal.</p>